SCHEDULE: MAIA Biotech CEO Boosts Stake to 9.66%

MAIA Biotechnology, Inc.'s CEO and Chairman, Vlad Vitoc, increased his beneficial ownership in the company to 9.66% through recent open market purchases and equity awards.

Summary

• Vlad Vitoc, the Chief Executive Officer and Chairman of MAIA Biotechnology, Inc., beneficially owns an aggregate of 3,846,352 shares of Common Stock.
• This ownership represents 9.66% of the company's outstanding Common Stock, calculated based on 39,805,300 shares outstanding as of December 2, 2025.
• The beneficially owned shares include 903,421 shares directly held by Mr. Vitoc, 210,100 shares directly held by his spouse, and 2,382,202 shares issuable upon the exercise of stock options and warrants directly held by Mr. Vitoc.
• Additional shares include 28,159 shares issuable upon exercise of stock options held by Mr. Vitoc's spouse, and 322,470 shares (161,235 each) issuable upon exercise of stock options held by two irrevocable trusts for the benefit of Mr. Vitoc's children, for which his spouse serves as trustee.
• Mr. Vitoc disclaims beneficial ownership of the shares held by his spouse and the two irrevocable trusts.
• Shares were acquired through grants of equity awards from the Issuer's incentive plans and through open market purchases using personal funds.
• During the past 60 days, Mr. Vitoc purchased a total of 94,300 shares of Common Stock in open market transactions, with prices ranging from $0.92 to $1.1366 per share.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the CEO and Chairman increasing his beneficial ownership through open market purchases, signaling confidence in the company's future prospects. This is a strong insider signal.

Positives

• The Chief Executive Officer and Chairman, Vlad Vitoc, has increased his beneficial ownership in the company to 9.66%, signaling strong insider confidence.
• Recent open market purchases by Mr. Vitoc totaling 94,300 shares demonstrate a direct investment in the company's stock.

Risks

• The Reporting Person may in the future acquire additional Common Stock or dispose of some or all of the Common Stock held.
• The Reporting Person may engage in short selling or hedging or similar transactions with respect to the Common Stock, subject to applicable law.

Future Outlook

The Reporting Person acquired the Common Stock for investment purposes and may in the future acquire additional shares or dispose of existing holdings. The Reporting Person also reserves the right to engage in short selling or hedging transactions and to formulate plans regarding investments in the company.

Industry Context

This filing is a standard disclosure of beneficial ownership by a key executive and does not provide specific industry context or trends. However, increased insider ownership in a biotechnology company can be viewed positively, suggesting confidence in future pipeline developments or market position.

Legal Proceedings

• The Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• The Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.

Related Party Transactions

• Shares are held by Mr. Vitoc's spouse and two irrevocable trusts for the benefit of his children, for which his spouse serves as trustee. Mr. Vitoc disclaims beneficial ownership of these shares.

Stakeholder Impact

• Shareholders may view the increased insider ownership by the CEO as a positive signal of management's confidence in the company's long-term value and prospects.

Next Steps

• The Reporting Person may acquire additional Common Stock or dispose of some or all of the Common Stock held.
• The Reporting Person may engage in short selling or hedging or similar transactions with respect to the Common Stock.

Key Dates

Recommendation

The CEO's increased stake signals confidence in the company's future, which is generally a positive indicator for investors. However, this filing does not provide financial performance data or strategic updates to warrant a stronger buy or sell recommendation. It primarily reflects an insider's investment decision.

Keywords

MAIA Biotechnology, Vlad Vitoc, Schedule 13D, Beneficial Ownership, Insider Buying, Common Stock, Equity Awards, Biotechnology, CEO Stake